Stock Price Quote

DISHMAN PHARMACEUTICALS & CHEMICALS LTD. - (AMALGAMATED)

NSE : NABSE : 532526ISIN CODE : INE353G01020Industry : Pharmaceuticals & DrugsHouse : Dishman Pharma
BSE301.050 (0 %)
PREV CLOSE ( ) 301.05
OPEN PRICE ( ) 293.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 301.05 (1375)
VOLUME 460499
TODAY'S LOW / HIGH ( )278.10 304.30
52 WK LOW / HIGH ( ) 278.1304.3
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1983
Management Info
Janmejay R Vyas - Chairman Arpit J Vyas - Managing Director
Registered Office

Address Bhadr Raj Chambers,Swastik Cross Road,Navrangpura,
Ahmedabad,
Gujarat-380009

Phone 079- 26443053 / 26445807 / 26560089

Email dishman@dishmangroup.com

Website www.dishmangroup.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

24Jul Dishman Pharma’s arm successfully comp
Dishman Pharmaceuticals and Chemicals’ wholly owned subsidiary Carbogen..
24Jul Dishman Pharma’s arm successfully comp
Dishman Pharmaceuticals and Chemicals’ wholly owned subsidiary Carbogen..
17May Dishman Pharmaceuticals & Chemicals in
Dishman Pharmaceuticals & Chemicals has informed that the meeting of..
20Apr Dishman Pharmaceuticals and Chemicals
Dishman Pharmaceuticals and Chemicals has submitted the Shareholding Pat..
04Apr Bhadra Raj Holdings submits disclosure
The Exchange has received the disclosure under Regulation 29(1) of SEBI..

Financials

in Millions
QTR Jun 17 ANNUAL 17
Net Profit-84.8242.4
Gross Profit -131.7 439.1
Operating Profit 283.62189.3
Net Sales 941.14514.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

MUTUAL FUNDS/UTI 9.57%
PROMOTERS 61.4%
NON-INSTITUTION 17.76%
FI/BANKS/INSURANCE 0.35%
FII 0.35%
GOVERNMENT 0%

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) was incorporated in the year 1983. Its today's share price is 301.05. Its current market capitalisation stands at Rs 4858.77 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5160.3 Cr and Total Income of Rs.5727.7 Cr. The company's management includes Shrima G Dave, Rajendra S Shah, Subir Kumar Das, Ashok C Gandhi, Sanjay S Majmudar, Mark Griffiths, Arpit J Vyas, Deohooti J Vyas, Janmejay R Vyas.

It is listed on the BSE with a BSE Code of 532526 , NSE with an NSE Symbol of DISHMAN and ISIN of INE353G01020. It's Registered office is at Bhadr Raj Chambers,Swastik Cross Road,NavrangpuraAhmedabad-380009, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, Haribhakti & Co LLP, Kunte & Associates., VD Shukla & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.